Edwards Lifesciences to Begin Clinical Trial of Transcatheter Valve

Edwards Lifesciences has received conditional approval from the FDA for the first cohort of a trial to study the company’s Sapien XT transcatheter heart valve. The first cohort will study up to 450 patients with severe, symptomatic aortic stenosis. The valve is already CE-Marked and is commercially available in Europe.